
Emi Takashita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6733045/publications.pdf Version: 2024-02-01



FMI TAKASHITA

#	Article	IF	CITATIONS
1	Characterization of H7N9 influenza A viruses isolated from humans. Nature, 2013, 501, 551-555.	13.7	371
2	Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New England Journal of Medicine, 2022, 386, 995-998.	13.9	301
3	Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. New England Journal of Medicine, 2022, 386, 1475-1477.	13.9	240
4	Effect of the Addition of Oligosaccharides on the Biological Activities and Antigenicity of Influenza A/H3N2 Virus Hemagglutinin. Journal of Virology, 2004, 78, 9605-9611.	1.5	184
5	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, 607, 119-127.	13.7	174
6	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Research, 2016, 132, 178-185.	1.9	155
7	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Research, 2015, 117, 27-38.	1.9	132
8	A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. Cell Host and Microbe, 2017, 22, 615-626.e8.	5.1	121
9	The Role of G-Protein-Coupled Receptor Kinase 5 in Pathogenesis of Sporadic Parkinson's Disease. Journal of Neuroscience, 2006, 26, 9227-9238.	1.7	116
10	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Research, 2018, 157, 38-46.	1.9	100
11	Increased risk of rhinovirus infection in children during the coronavirus diseaseâ€19 pandemic. Influenza and Other Respiratory Viruses, 2021, 15, 488-494.	1.5	97
12	Reactivation of Herpes Simplex Virus Type 1 and Varicella-Zoster Virus and Therapeutic Effects of Combination Therapy With Prednisolone and Valacyclovir in Patients With Bell??s Palsy. Laryngoscope, 2007, 117, 147-156.	1.1	94
13	Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Eurosurveillance, 2019, 24, .	3.9	93
14	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018. Antiviral Research, 2020, 175, 104718.	1.9	91
15	Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Eurosurveillance, 2019, 24, .	3.9	88
16	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Research, 2017, 146, 12-20.	1.9	87
17	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Research, 2014, 110, 31-41.	1.9	85
18	Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerging Infectious Diseases, 2019, 25, 2108-2111.	2.0	81

ΕΜΙ ΤΑΚΑSΗΙΤΑ

#	Article	IF	CITATIONS
19	Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Frontiers in Microbiology, 2018, 9, 3026.	1.5	74
20	Characterization of a Large Cluster of Influenza A(H1N1)pdm09 Viruses Cross-Resistant to Oseltamivir and Peramivir during the 2013-2014 Influenza Season in Japan. Antimicrobial Agents and Chemotherapy, 2015, 59, 2607-2617.	1.4	69
21	Replication-incompetent influenza A viruses that stably express a foreign gene. Journal of General Virology, 2011, 92, 2879-2888.	1.3	64
22	Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Research, 2016, 132, 170-177.	1.9	62
23	A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virology Journal, 2010, 7, 53.	1.4	59
24	A Nationwide Epidemic of Influenza C Virus Infection in Japan in 2004. Journal of Clinical Microbiology, 2007, 45, 783-788.	1.8	54
25	Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038687.	2.9	45
26	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020. Antiviral Research, 2022, 200, 105281.	1.9	44
27	Identification of an amino acid residue on influenza C virus M1 protein responsible for formation of the virus. Journal of General Virology, 2004, 85, 1885-1893.	1.3	41
28	A Mutation on Influenza C Virus M1 Protein Affects Virion Morphology by Altering the Membrane Affinity of the Protein. Journal of Virology, 2007, 81, 8766-8773.	1.5	40
29	Influenza C Virus CM2 Protein Is Produced from a 374-Amino-Acid Protein (P42) by Signal Peptidase Cleavage. Journal of Virology, 1999, 73, 46-50.	1.5	37
30	Genetic diversity of influenza B virus: The frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community. Journal of Medical Virology, 2004, 74, 132-140.	2.5	36
31	Molecular Evolutionary Analysis of the Influenza A(H1N1)pdm, May–September, 2009: Temporal and Spatial Spreading Profile of the Viruses in Japan. PLoS ONE, 2010, 5, e11057.	1.1	36
32	A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochemical and Biophysical Research Communications, 2012, 429, 51-56.	1.0	33
33	Evaluation of a New Rapid Antigen Test Using Immunochromatography for Detection of Human Metapneumovirus in Comparison with Real-Time PCR Assay. Journal of Clinical Microbiology, 2009, 47, 2981-2984.	1.8	31
34	Monitoring and Characterization of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Japan, 2009–2010. Emerging Infectious Diseases, 2011, 17, 470-479.	2.0	30
35	Evaluation of Influenza Virus A/H3N2 and B Vaccines on the Basis of Cross-Reactivity of Postvaccination Human Serum Antibodies against Influenza Viruses A/H3N2 and B Isolated in MDCK Cells and Embryonated Hen Eggs. Vaccine Journal, 2012, 19, 897-908.	3.2	30
36	Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018–2019 Influenza Season. Journal of Infectious Diseases, 2020, 222, 121-125.	1.9	30

Εμι Τακάσηιτα

#	Article	IF	CITATIONS
37	Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Eurosurveillance, 2016, 21, .	3.9	30
38	Longitudinal course of human metapneumovirus antibody titers and reinfection in healthy adults. Journal of Medical Virology, 2010, 82, 2092-2096.	2.5	27
39	Characterization of neuraminidase inhibitorâ€resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and postâ€pandemic periods in <scp>J</scp> apan. Influenza and Other Respiratory Viruses, 2013, 7, 1390-1399.	1.5	26
40	A Novel Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice from Pandemic H1N1 and Highly Pathogenic H5N1 Virus Challenges. Journal of Virology, 2013, 87, 7874-7881.	1.5	25
41	C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 1902-1906.	1.4	25
42	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Research, 2021, 194, 105158.	1.9	24
43	Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment. Antiviral Research, 2020, 180, 104828.	1.9	22
44	6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential. Journal of Antimicrobial Chemotherapy, 2015, 70, 2797-2809.	1.3	21
45	Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Scientific Reports, 2017, 7, 17735.	1.6	21
46	Influenza C Virus NS1 Protein Upregulates the Splicing of Viral mRNAs. Journal of Virology, 2010, 84, 1957-1966.	1.5	20
47	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nature Microbiology, 2022, 7, 1252-1258.	5.9	20
48	Role of the CM2 Protein in the Influenza C Virus Replication Cycle. Journal of Virology, 2011, 85, 1322-1329.	1.5	19
49	TMPRSS2 Independency for Haemagglutinin Cleavage In Vivo Differentiates Influenza B Virus from Influenza A Virus. Scientific Reports, 2016, 6, 29430.	1.6	19
50	Rapid discrimination of oseltamivirâ€resistant 275Y and â€susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex oneâ€step RTâ€PCR assay. Journal of Medical Virology, 2011, 83, 1121-1127.	2.5	18
51	Induction of Bcl-2 gene expression by intercellular information from hemopoietic supportive stromal cells to DA-1 cells. Journal of Cellular Physiology, 1994, 161, 367-373.	2.0	15
52	Comparison of virus isolation using the Vero E6 cell line with real-time RT-PCR assay for the detection of human metapneumovirus. BMC Infectious Diseases, 2010, 10, 170.	1.3	15
53	Development and evaluation of a whole virus-based enzyme-linked immunosorbent assay for the detection of human metapneumovirus antibodies in human sera. Journal of Virological Methods, 2010, 164, 24-29.	1.0	14
54	Intrinsic Temperature Sensitivity of Influenza C Virus Hemagglutinin-Esterase-Fusion Protein. Journal of Virology, 2012, 86, 13108-13111.	1.5	14

ΕΜΙ ΤΑΚΑSΗΙΤΑ

#	Article	IF	CITATIONS
55	Induction of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Granulocyte Colony-Stimulating Factor (G-CSF) Expression in Bone Marrow and Fractionated Marrow Cell Populations by Interleukin 3 (IL-3): IL-3-Mediated Positive Feedback Mechanisms of Granulopoiesis. Growth Factors, 1994, 11, 71-79.	0.5	13
56	Intracellular localization of influenza C virus NS2 protein (NEP) in infected cells and its incorporation into virions. Archives of Virology, 2009, 154, 235-243.	0.9	10
57	Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. BMC Infectious Diseases, 2020, 20, 478.	1.3	10
58	Mutations at the monomer–monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs. Journal of Infection and Chemotherapy, 2013, 19, 891-895.	0.8	8
59	In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients. Pathogens, 2020, 9, 725.	1.2	8
60	Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil. Influenza and Other Respiratory Viruses, 2020, 14, 436-443.	1.5	8
61	Separate Control of the Survival, the Self-renewal and the Differentiation of Hemopoietic Stem Cells Cell Structure and Function, 1995, 20, 117-124.	0.5	7
62	Isolation of an Influenza C Virus Introduced into Japan by a Traveler from Malaysia. Journal of Clinical Microbiology, 2005, 43, 993-995.	1.8	7
63	Conformational maturation of the nucleoprotein synthesized in influenza C virus-infected cells. Virus Research, 2006, 122, 45-52.	1.1	7
64	Seroprevalence of a Novel Influenza A (H3N2) Variant Virus in the Japanese Population. Japanese Journal of Infectious Diseases, 2013, 66, 549-551.	0.5	6
65	Location of a linear epitope recognized by monoclonal antibody S16 on the hemagglutinin-esterase glycoprotein of influenza C virus. Virus Research, 1999, 61, 53-61.	1.1	5
66	Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019–2020 Influenza Season. Journal of Infectious Diseases, 2021, , .	1.9	4
67	Constitutive production of IL-6 in the anemic mice of genotype. Leukemia Research, 1994, 18, 123-131.	0.4	3
68	Characterization of an A (H1N1)pdm09 Virus Imported from India in March 2015. Japanese Journal of Infectious Diseases, 2016, 69, 83-86.	0.5	3
69	Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin. Japanese Journal of Infectious Diseases, 2018, 71, 234-238.	0.5	3
70	Strain Specific Production of a Negative Regulator of IL-3 (NIL-3): Difference in the Negative Feedback Mechanism of Hemopoiesis among Mouse Strains Cell Structure and Function, 1997, 22, 407-411.	0.5	1
71	Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019. Japanese Journal of Infectious Diseases, 2020, 73, 386-390.	0.5	1
72	Antiviral susceptibilities of avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan. Japanese Journal of Infectious Diseases, 2021, , .	0.5	1

ΕΜΙ ΤΑΚΑSΗΙΤΑ

#	Article	IF	CITATIONS
73	Gene Expression of Lipid Binding Protein Transferred the Ability of Specific Attachment of Hemopoietic Cells to Non-supportive Stromal Cell Line, MS-K Cell Structure and Function, 1997, 22, 595-602.	0.5	Ο
74	Mutual Education Between Hematopoietic Cells and Bone Marrow Stromal Cells Through Direct Cell-to-Cell Contact: Factors That Determine the Growth of Bone Marrow Stroma-Dependent Leukemic (HB-1) Cells. Blood, 1998, 92, 834-841.	0.6	0
75	Viruses Resistant to Oseltamivir orÂBaloxavir: What Do the Data Reveal About Resistance?. Respiratory Disease Series, 2021, , 221-229.	0.1	0